Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

Pfizer (NYSE:PFE) and Bristol Myers Squibb are making their blood thinner Eliquis available through the Mark Cuban Cost Plus ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Pfizer (NYSE: PFE) has become the dividend investor's siren song. With shares down 31% over the past five years and a current yield of 7%, the pharmaceutical giant offers one of the juiciest payouts ...

The news: Novo Nordisk and Pfizer have both sweetened their bids for the US obesity-focused biotech Metsera, as the two pharmaceutical giants battle to land one of the world’s most promising ...

Pfizer PFE reported a 2% decline in revenue and a 4% increase in adjusted EPS in 2025, and management maintained 2026 revenue guidance for $59.5 billion-$62.5 billion (between flat and a 5% decline) ...